

## TriLink, QuantiBact ink licensing deal, 7/13:104

TriLink BioTechnologies has signed a licensing agreement with QuantiBact to offer twisted intercalating nucleic acid (TINA) modified oligonucleotides.

TINA molecules are intercalators placed at the 5' end of primers to stabilize duplex formation. Their properties improve the sensitivity and specificity of endpoint and real-time PCR. TINA oligos may find applications wherever an enhanced  $T_m$  is required, such as triplex formation or gene silencing.

TINA-modified oligonucleotides are now available from TriLink. Visit [trilink-biotech.com/TINA](http://trilink-biotech.com/TINA) for up-to-date information.

**TriLink BioTechnologies**, 800-863-6801